Magnetic Marker Localization for Occult Breast Cancer and Target Axillary Dissection in Node-positive Breast Cancer Post-neoadjuvant Chemotherapy

Chemotherapy Effect Clinical Trial

— MaCTAD  

Official title:

Magnetic Marker Localization for Occult Breast Cancer and Target Axillary Dissection in Node-positive Breast Cancer Post-neoadjuvant Chemotherapy

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05427071
• Other study ID #: UW 20-064
• Status: Recruiting
• Phase: N/A
• Start date: October 15, 2020
• Est. completion date: December 31, 2028

Study information

• Verified date: June 2022
• Source: The University of Hong Kong
• Contact: Chi Mei Vivian Man, FCSHK, FRCSEd
• Phone: 852-25898116
• Email: vivian27[@]hku.hk
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The use of neoadjuvant chemotherapy in breast cancer is expanding in the recent decade. Patients with good response to neoadjuvant chemotherapy could benefit from de-escalation of breast and axilla operation. However, breast tumor and involved axillary lymph node should be marked before the commencement of chemotherapy. This could facilitate subsequent operative planning and intraoperative assessment of disease response. This study aims to evaluate the feasibility of magnetic marker localization for non-palpable breast cancer and targeted axillary dissection in patients with node-positive breast cancer following neoadjuvant therapy

Description:

Eligible patients will receive ultrasound guided placement of magnetic seeds (Magseed®) within the cortex of the sampled lymph node and epicenter of the breast tumor by radiologists before commencement of neoadjuvant treatment. Chemotherapeutic regimes will be determined by oncologists in charge. During the period of neoadjuvant treatment, patients will be followed up by oncologists and surgeons with clinical assessment of tumor response according to our usual practice. After completion of neoadjuvant chemotherapy, recruited patients will receive mammography and ultrasonography assessment before surgery. Breast conservative surgery with targeted axillary dissection will be offered when feasible. In patients not suitable for breast conservative surgery, mastectomy and targeted axillary dissection with or without immediate breast reconstruction will be offered.

Patient will receive localization of previously marked axillary lymph node and breast tumor and sentinel lymph node biopsy by magnetic means completely, i.e. by the use if magnetic seeds and superparamagnetic iron oxide injection. Radioisotope with Tc-99 is injected prior to operation as backup plan for sentinel lymph node biopsy. The clipped lymph node and sentinel lymph nodes are sent for frozen section analysis. If any of the lymph nodes is positive for malignancy, axillary dissection will be performed. Similarly, the breast tumor will be resected with guidance of magnetometer and specimen mammogram will confirm the presence of tumor and magnetic seeds.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: December 31, 2028
• Est. primary completion date: December 31, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• All patients with cT1-3N1 invasive ductal carcinoma planned for neoadjuvant chemotherapy and/or target therapy

• mentally competent to give informed consent

• Agreed to proceed with curative operation after chemotherapy and tentatively keen for breast conservative surgery and targeted axillary dissection after neoadjuvant chemotherapy

• Radiologically 1-3 ipsilateral axillary lymph node metastases confirmed by cytology or biopsy

Exclusion Criteria:

• Presence of distant metastasis, inflammatory breast cancers, multi-centric breast cancers

• History of previous ipsilateral axillary surgery or irradiation

• Hypersensitivity to dextran compounds or iron

• Iron overload disease

• Pregnant or lactating patients

• Patients with pacemaker or other implantable metallic devices in chest wall or prosthesis in shoulder

• Mentally incompetent patients

Related Conditions & MeSH terms

• Breast Neoplasm
• Breast Neoplasms
• Chemotherapy Effect

Intervention

Device:
• Magnetic seed localization
Magnetic seed guided localization

Locations

Country	Name	City	State
Hong Kong	University of Hong Kong	Hong Kong

Sponsors (2)

Lead Sponsor	Collaborator
The University of Hong Kong	Endomagnetics Ltd.

Country where clinical trial is conducted

Hong Kong, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Successful localization of breast tumor and axillary lymph node	Successful surgical retrieval of magnetic seed marked breast tumor and axillary lymph node in intraoperative specimen mammogram (in percentage)	At the time of operation
Secondary	Percentage of patients that can avoid axillary lymph node dissection	Percentage of patients that can achieve nodal pathological complete response after neoadjuvant chemotherapy	up to 4 weeks
Secondary	Percentage of successful magnetic seed guided lumpectomy	Percentage of involved or close margins in lumpectomy specimen which require re-excision	up to 4 weeks
Secondary	Level of satisfaction from surgeons and radiologists	Level of satisfaction from surgeons and radiologists which will be determined by the satisfaction questionnaire	To be filled in by operating surgeons and radiologists at the time of operation or magnetic seeds placement
Secondary	5-year local regional recurrence rate	5-year ipsilateral breast tumor recurrence rate and/or axillary recurrence rate	5-year post-operatively